111301-96-3

Basic information

• Product Name: Pyridine, 3-nitro-2-(phenylmethoxy)-
• CAS NO: 111301-96-3
• Molecular Formula: C12H10N2O3
• Molecular Weight: 230.223
• Mol File: 111301-96-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Pyridine, 3-nitro-2-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 3-nitro-2-(phenylmethoxy)-(111301-96-3)
• EPA Substance Registry System: Pyridine, 3-nitro-2-(phenylmethoxy)-(111301-96-3)

Safety Data

• Hazardous Substances Data: 111301-96-3(Hazardous Substances Data)

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 100-51-6 benzyl alcohol 

Downstream Products

• 5470-18-8 2-Chloro-3-nitropyridine 
• 23845-96-7 2-(benzyloxy)pyridin-3-amine 

Relevant articles and documents

Design, synthesis and fungicidal evaluation of novel pyraclostrobin analogues

A series of novel pyraclostrobin derivatives were designed and prepared as antifungal agents. Their antifungal activities were tested in vitro with five important phytopathogenic fungi, namely, Batrylis cinerea, Phytophthora capsici, Fusarium sulphureum, Gloeosporium pestis and Sclerotinia sclerotiorum using the mycelium growth inhibition method. Among these compounds, 5s displayed IC50 value of 0.57 μg/mL against Batrylis cinerea and 5k-II displayed IC50 value of 0.43 μg/mL against Sclerotinia sclerotiorum, which were close to that of the positive control pyraclostrobin (0.18 μg/mL and 0.15 μg/mL). Other compounds 5f, 5k-II, 5j, 5m and 5s also exhibited strong antifungal activity. Further enzymatic assay demonstrated compound 5s inhibited porcine bc1 complex with IC50 value of 0.95 μM. The statistical results from an integrated computational pipeline demonstrated the predicted total binding free energy for compound 5s is the highest. Consequently, compound 5s with the biphenyl-4-methoxyl side chain could serve as a new motif as inhibitors of bc1 complex and deserve to be further investigated.

PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES

Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRROLO[2,3-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

The present invention provides novel pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump inhibitory effect.